Sarah Ketterer
Causeway Capital Management
Sarah Ketterer GlaxoSmithKline PLC ADR stake
total: 372
Causeway Capital Management GSK trades
- Total transactions:
- 37
- New positions:
- 2
- Sold out:
- 1
- Added:
- 18
- Reduced:
- 16
- Held since:
- 2021 Q4
- Held for:
- 19 quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Sarah Ketterer holds 7,163 GlaxoSmithKline PLC ADR (GSK) shares with a market value of roughly $375.47K accounting for 0.00% of the overall portfolio. To date, the estimated cost basis is nearly $39.99 for "buy" trades and estimated average "sell" price is $48.51. Causeway Capital Management first purchased GSK in 2015 Q1, initially acquiring 351,691 shares. Sarah Ketterer later completely sold out the position and invested in GlaxoSmithKline PLC ADR again in 2021 Q4. Since the initial investment in GlaxoSmithKline PLC ADR (GSK), Causeway Capital Management has made 36 more transactions.
When did Sarah Ketterer buy GlaxoSmithKline PLC ADR (GSK)?
Sarah Ketterer first invested in GlaxoSmithKline PLC ADR (GSK) in 2015 Q1 at the reported quarter-end price of $57.69 per share.
What's the cost basis of Causeway Capital Management's GSK stake?
The estimated cost basis for GlaxoSmithKline PLC ADR (GSK) stake is around $39.99 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $39.99
- Weighted AVG sell price:
- $48.51
Sarah Ketterer's historical trades in GlaxoSmithKline PLC ADR
37 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
0.00%
|
7,163
|
$52.42
|
$375,470
|
-35.53% (-3,947)
|
-0%
|
|
2026 Q1
|
0.01%
|
11,110
|
$55.19
|
$613,177
|
-67.22% (-22,787)
|
-0.02%
|
|
2025 Q4
|
0.02%
|
33,897
|
$49.04
|
$1,662,321
|
-97.12% (-1,143,104)
|
-0.74%
|
|
2025 Q3
|
0.67%
|
1,177,001
|
$43.16
|
$50,799,344
|
+6.32% (+69,925)
|
+0.04%
|
|
2025 Q2
|
0.67%
|
1,107,076
|
$38.40
|
$42,511,705
|
-0.08% (-847)
|
-0%
|
|
2025 Q1
|
0.90%
|
1,107,923
|
$38.74
|
$42,920,943
|
+2.91% (+31,343)
|
+0.03%
|
|
2024 Q4
|
0.83%
|
1,076,580
|
$33.82
|
$36,409,929
|
+19.97% (+179,174)
|
+0.14%
|
|
2024 Q3
|
0.90%
|
897,406
|
$40.88
|
$36,685,942
|
+19.09% (+143,871)
|
+0.14%
|
|
2024 Q2
|
0.79%
|
753,535
|
$38.50
|
$29,011,113
|
+2.22% (+16,350)
|
+0.02%
|
|
2024 Q1
|
0.83%
|
737,185
|
$42.87
|
$31,603,132
|
-7.32% (-58,256)
|
-0.06%
|
|
2023 Q4
|
0.75%
|
$37.06
|
+40.85% (+230,694)
|
|||
|
2023 Q3
|
0.54%
|
$36.25
|
+41.39% (+165,317)
|
|||
|
2023 Q2
|
0.37%
|
$35.64
|
+25.15% (+80,270)
|
|||
|
2023 Q1
|
0.27%
|
$35.58
|
+34.65% (+82,127)
|
|||
|
2022 Q4
|
0.24%
|
$35.14
|
+29.14% (+53,489)
|
|||
|
2022 Q3
|
0.15%
|
$29.43
|
-11.13% (-22,986.4)
|
|||
|
2022 Q2
|
0.28%
|
$54.41
|
-0.08% (-172)
|
|||
|
2022 Q1
|
0.27%
|
$54.45
|
+44.71% (+63,865.6)
|
|||
|
2021 Q4
|
0.17%
|
$55.13
|
new
|
|||
|
2019 Q2
|
0.00%
|
$51.83
|
-100% (-1,138.4)
|
|||
|
2019 Q1
|
0.00%
|
$51.83
|
-99.50% (-226,534.4)
|
|||
|
2018 Q4
|
0.13%
|
$47.76
|
-27.02% (-84,311.2)
|
|||
|
2018 Q3
|
0.16%
|
$50.21
|
-9.00% (-30,836.8)
|
|||
|
2018 Q2
|
0.17%
|
$50.39
|
-53.46% (-393,800.8)
|
|||
|
2018 Q1
|
0.39%
|
$48.84
|
+46.12% (+232,491.2)
|
|||
|
2017 Q4
|
0.24%
|
$44.34
|
+14.39% (+63,402.4)
|
|||
|
2017 Q3
|
0.25%
|
$50.75
|
+29.61% (+100,690.4)
|
|||
|
2017 Q2
|
0.23%
|
$53.90
|
+34.72% (+87,625.6)
|
|||
|
2017 Q1
|
0.18%
|
$52.70
|
+7.11% (+16,764)
|
|||
|
2016 Q4
|
0.19%
|
$46.88
|
-10.04% (-26,287.2)
|
|||
|
2016 Q3
|
0.26%
|
$53.91
|
-0.72% (-1,905.6)
|
|||
|
2016 Q2
|
0.30%
|
$54.18
|
-26.78% (-96,483.2)
|
|||
|
2016 Q1
|
0.44%
|
$53.64
|
-13.10% (-54,296)
|
|||
|
2015 Q4
|
0.44%
|
$50.44
|
-14.52% (-70,432)
|
|||
|
2015 Q3
|
0.47%
|
$48.06
|
+19.44% (+78,947.2)
|
|||
|
2015 Q2
|
0.53%
|
$52.06
|
+15.47% (+54,413.6)
|
|||
|
2015 Q1
|
0.53%
|
$57.69
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.